Temporal trends on the prevalence of renal disease and outcomes among patients with diabetes mellitus hospitalized by heart failure: findings from INCAex

References

• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241(19):2035–2038. doi: 10.1001/jama.1979.03290450033020
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628–1637. doi: 10.1016/S0735-1097(00)00582-9
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. doi: 10.2337/diacare.27.5.1047
   PubMed Web of Science ®Google Scholar
• From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119(7):591–599. doi: 10.1016/j.amjmed.2006.05.024
   PubMed Web of Science ®Google Scholar
• Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation. 1993;88(1):107–115. doi: 10.1161/01.CIR.88.1.107
   PubMed Web of Science ®Google Scholar
• Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61–67. doi: 10.1016/j.jacc.2003.07.031
   PubMed Web of Science ®Google Scholar
• Casado J, Montero M, Formiga F, et al. Clinical characteristics and prognostic influence of renal dysfunction in heart failure patients with preserved ejection fraction. Eur J Intern Med. 2013;24(7):677–683. doi: 10.1016/j.ejim.2013.06.003
   PubMed Web of Science ®Google Scholar
• Ferreira JP, Kraus BJ, Zwiener I, et al. Cardio/Kidney composite end points: a post hoc analysis of the EMPA-REG OUTCOME trial. J Am Heart Assoc. 2021;10(7):e020053. doi: 10.1161/JAHA.120.020053
   PubMed Web of Science ®Google Scholar
• Neuen BL, Ohkuma T, Neal B, et al. Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program. Am J Kidney Dis. 2021;77(1):23–34.e1. doi: 10.1053/j.ajkd.2020.06.018
   PubMed Web of Science ®Google Scholar
• Cahn A, Raz I, Leiter LA, et al. Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58. Diabetes Care. 2021;44(5):1159–1167. doi: 10.2337/dc20-2492
   PubMed Web of Science ®Google Scholar
• Kim MK, Kim DM. Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients. J Diabetes Investig. 2021;12(6):914–916. doi: 10.1111/jdi.13552
   PubMed Web of Science ®Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of Empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143(4):310–321. doi: 10.1161/CIRCULATIONAHA.120.051685
   PubMed Web of Science ®Google Scholar
• Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298–309. doi: 10.1161/CIRCULATIONAHA.120.050391
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi: 10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Fernández-Bergés D, Consuegra-Sánchez L, Félix-Redondo FJ, et al. Características clínicas y mortalidad de la insuficiencia cardiaca. Estudio INCAex. Revista Clínica Española. 2013;213(1):16–24. doi: 10.1016/j.rce.2012.07.004
   PubMedGoogle Scholar
• Lawson CA, Seidu S, Zaccardi F, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine. 2021;32:100739. doi: 10.1016/j.eclinm.2021.100739
   PubMedGoogle Scholar
• Levin A, Stevens PE. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85(1):49–61. doi: 10.1038/ki.2013.444
   PubMed Web of Science ®Google Scholar
• Echouffo-Tcheugui JB, Xu H, DeVore AD, et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from get with the guidelines-heart failure registry. Am Heart J. 2016;182:9–20. doi: 10.1016/j.ahj.2016.07.025
   PubMed Web of Science ®Google Scholar
• Wong CY, Chaudhry SI, Desai MM, et al. Trends in comorbidity, disability, and polypharmacy in heart failure. Am J Med. 2011;124(2):136–143. doi: 10.1016/j.amjmed.2010.08.017
   PubMed Web of Science ®Google Scholar
• Win TT, Davis HT, Laskey WK. Mortality among patients hospitalized with heart failure and diabetes mellitus: results from the national inpatient sample 2000 to 2010. Circ Heart Fail. 2016;9(5):e003023. doi: 10.1161/CIRCHEARTFAILURE.115.003023
   PubMed Web of Science ®Google Scholar
• Méndez-Bailón M, Jiménez-García R, Hernández-Barrera V, et al. Significant and constant increase in hospitalization due to heart failure in Spain over 15 year period. Eur J Intern Med. 2019;64:48–56. doi: 10.1016/j.ejim.2019.02.019
   PubMed Web of Science ®Google Scholar
• Félix-Redondo FJ, Fernández-Bergés D, Fernando Pérez J, et al. Prevalencia, detección, tratamiento y grado de control de los factores de riesgo cardiovascular en la población de Extremadura (España). Estudio HERMEX [Prevalence, awareness, treatment and control of cardiovascular risk factors in the Extremadura population (Spain). HERMEX study]. Aten Primaria. 2011;43(8):426–434. doi: 10.1016/j.aprim.2010.07.008
   PubMedGoogle Scholar
• Grau M, Elosua R, Cabrera de León A, et al. Factores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS [Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study]. Rev Esp Cardiol. 2011;64(4):295–304. doi: 10.1016/j.recesp.2010.11.005
   PubMed Web of Science ®Google Scholar
• Rojo-Martínez G, Valdés S, Soriguer F, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort [email protected] study. Sci Rep. 2020;10(1):2765. doi: 10.1038/s41598-020-59643-7
   PubMedGoogle Scholar
• Heywood JT, Fonarow GC, Costanzo MR, et al. ADHERE scientific advisory committee and investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–430. doi: 10.1016/j.cardfail.2007.03.011
   PubMed Web of Science ®Google Scholar
• van Deursen VM, Urso R, Laroche C, et al. Co-morbidities in patients with heart failure: an analysis of the European heart failure pilot survey. Eur J Heart Fail. 2014;16:103–111. doi: 10.1002/ejhf.30
   PubMed Web of Science ®Google Scholar
• Pandey A, Vaduganathan M, Arora S, et al. Temporal trends in prevalence and prognostic implications of comorbidities among patients with acute decompensated heart failure: the ARIC study community surveillance. Circulation. 2020;142(3):230–243. doi: 10.1161/CIRCULATIONAHA.120.047019
   PubMed Web of Science ®Google Scholar
• de Boer Ih, de Boer IH, Rue TC, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539. doi: 10.1001/jama.2011.861
   PubMed Web of Science ®Google Scholar
• Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J. 2007;154(2):277.e1–8. doi: 10.1016/j.ahj.2007.05.001
   PubMed Web of Science ®Google Scholar
• De Groote P, Lamblin N, Mouquet F, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004;25(8):656–662. doi: 10.1016/j.ehj.2004.01.010
   PubMed Web of Science ®Google Scholar
• Kong MG, Jang SY, Jang J, et al. Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study. Cardiovasc Diabetol. 2020;19(1):49. doi: 10.1186/s12933-020-01026-3
   PubMedGoogle Scholar
• Bauters C, Lamblin N, Mc Fadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol. 2012;2(1):1. doi: 10.1186/1475-2840-2-1
   Google Scholar
• Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metabol. 2012;15(5):635–645. doi: 10.1016/j.cmet.2012.04.001
   PubMed Web of Science ®Google Scholar
• Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2020;120(5):1506–1514. doi: 10.1172/JCI40096
   Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. EMPEROR-Reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646–659. doi: 10.1161/CIRCRESAHA.113.300268
   PubMed Web of Science ®Google Scholar